947673-13-4

Upstream product

• 31166-44-6 phenylmethyl 1-piperazinecarboxylate 
• 350-46-9 4-Fluoronitrobenzene 
• 260252-87-7 1-(4-nitrophenyl)piperazine hydrochloride 
• 501-53-1 benzyl chloroformate 
• 6269-89-2 1-(4-Nitrophenyl)piperazine 

Downstream Products

• 1566584-32-4 benzyl 4-(4-((4-(2-(2-methoxy-2-oxoethyl)phenethyl)pyrimidin-2-yl)amino)phenyl)piperazine-1-carboxylate 
• 1566651-77-1 2-(2-(2-(2-((4-(4-((benzyloxy)carbonyl)piperazin-1-yl)phenyl)amino)pyrimidine-4-yl)ethyl)phenyl)acetic acid 
• 1566584-34-6 benzyl 4-(4-((4-(2-(2-amino-2-oxoethyl)phenethyl)pyrimidin-2-yl)amino)phenyl)piperazine-1-carboxylate 
• 1566583-79-6 2-(2-(2-(2-((4-(piperazine-1-yl)phenyl)amino)pyrimidin-4-yl)ethyl)phenyl)acetamide 
• 1092542-97-6 C₂₈H₂₈Cl₂N₆O 
• 1092542-99-8 C₂₈H₂₉ClN₆O 
• 1092543-00-4 C₂₉H₃₂N₆O 
• 1092067-38-3 C₂₇H₂₈Cl₂N₄OS 
• 1092070-00-2 CH₄O₃S*C₃₁H₃₅Cl₂N₅O₃ 
• 1092068-34-2 C₃₂H₃₈Cl₂N₆O₅S 
• 1092068-66-0 C₃₁H₃₅Cl₂N₅O₄ 
• 1092068-68-2 C₃₁H₃₅Cl₂N₅O₅ 
• 1092067-85-0 N-[2,6-dichloro-4-(pyrrolidin-1-ylmethyl)phenyl]4-(4-{[(4-methoxyphenyl)-acetyl]amino}phenyl)piperazine-1-carboxamide 
• 1092065-41-2 C₂₈H₂₇Cl₂F₃N₄O₃ 

Relevant academic research and scientific papers

FUSED PYRIMIDINE PYRIDINONE COMPOUNDS AS JAK INHIBITORS

The disclosure provides compounds of formula (I), or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The disclosure also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal inflammatory diseases.

Imidazole derivatives, its pharmaceutical composition and use thereof

Imidazolone compounds, pharmaceutically acceptable salts, solvates, polymorphs or prodrugs thereof are disclosed. Pharmaceutical compositions comprising above substances and uses for preventing and treating protein kinases related diseases, such as cancers, metabolic diseases, cardiovascular diseases and the like, are also disclosed.

VEGFR3 INHIBITORS

This invention relates to compounds of the formula (I). The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphanglogenesis.

PIPERIDINE/PIPERAZINE DERIVATIVES

The invention relates to a DGAT inhibitor of formula (I) including any stereochemically isomeric form thereof, wherein A represents CH or N; X represents O or NRx; the dotted line represents an optional bond in case A represents a carbon atom;

PIPERIDINE/PIPERAZINE DERIVATIVES

The invention relates to a DGAT inhibitor of formula (I): including any stereochemically isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents -C(=O)-; -O-C(=O)-; -C(=O)-C(=O)-; -NRx-C(=O)-; -Z1-C(O)-; -Z1-NRx-C(=O)-; -C(=O)-Z1-; -NRx-C(=O)-Z1-; -S(=O)p-; -C(=S)-; -NRx-C(=S)-; -Z1-C(=S)-; -Z1-NRX-C(=S)-; -C(=S)-Z1-; -NRx-C(=S)-Z1-; Y represents NRx-C(=0)- Z2-; -NRx-C(=0)-Z2-NRy-; -NRx-C(=0)-Z2-NRy-C(=0)-; -NRx-C(=0)-Z2-NRy-C(=0)- O-; -NRx-C(=0)-Z2-0-; -NRx-C(=0)-Z2-0-C(=0)-; -NRx-C(=0)-Z2-C(=0)-; -NRx-C(=0)-Z2-C(=0)-0-; -NRx-C(=0)-0-Z2-C(=0)-; -NRx-C(=0)-0-Z2-C(=0)-0-; -NRx-C(=O)-O-Z2-O-C(=O)-; -NRx-C(=O)-Z2-C(=O)-NRy-; -NRx-C(=O)-Z2-NRy- C(=0)-NRy-; -C(=O)-Z2-; -C(=O)-Z2-O-; -C(=0)-NRx-Z2-; -C(=0)-NRx-Z2-0-; -C(=0)-NRx-Z2-C(=0)-0-; -C(=0)-NRx-Z2-0-C(=0)-; -C(=0)-NRx-0-Z2-; -C(=O)- NRx-Z2-NRy-; -C(=0)-NRx-Z2-NRy-C(=0)-; -C(=0)-NRx-Z2-NRy-C(=0)-0-; R1 represents C1-12alkyl optionally substituted with cyano, C1-4alkyloxy, C1-4alkyl-oxyC1-4alkyloxy, C3-6Cy cloalkyl or aryl; C2-6alkenyl; C2-6alkynyl; C3-6cycloalkyl; adamantanyl; aryl1; aryl1C1-6alkyl; Het1; or Het1C1-6alkyl; provided that when Y represents -NRX-C(=O)-Z2-; -NRx-C(=0)-Z2-NRy; -NRX-C(=O)-Z2-C(=O)- NRy-; -C(=O)-Z2-; -NRx-C(=0)-Z2-NRy-C(=0)-NRy-; -C(=O)-NRX-Z2-; -C(=O)-NRX- O-Z2-; or -C(=0)-NRx-Z2-NRy-; then R1 may also represent hydrogen; R2 represents hydrogen, C1-12alkyl, C2-6alkenyl or R3; provided that if X represents -O-C(=O)-, then R2 represents R3; and provided that is excluded; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds.

NEW COMPOUNDS

The present invention encompasses compounds of general formula (1) wherein X and R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.

New Compounds

The present invention encompasses compounds of general formula (1) wherein R1 to R6, X and Y are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or anomalous cell proliferation, as well as the use thereof for preparing a pharmaceutical composition with the above-mentioned properties.